PSMA PET在前列腺癌中的临床价值、可及性挑战与实施优先级
本文为专家视角文章,讨论PSMA PET在前列腺癌管理中的整合作用,包括高风险初诊分期和生化复发中的疾病特征描述,并指出其诊断性能优于传统影像且影响治疗规划与分层。文章强调尽管国际指南逐步纳入,但报销政策、监管框架、示踪剂供应、影像容量、转诊路径和本地专业能力差异导致欧洲各国可及性不均,可能影响分期准确性、复发定位、治疗选择与公平性。
要点
- PSMA PET已整合入前列腺癌管理,在高风险初诊分期和生化复发中改善疾病特征描述。
- 其诊断性能优于传统影像,并日益影响治疗规划、患者分层和多学科决策。
- 报销、监管、示踪剂供应、影像容量、转诊路径和本地专业能力差异导致可及性不均。
核心结论
- 改善高质量PSMA PET的可及性不仅是后勤目标,更是确保分子影像进步转化为更精准、及时和公平前列腺癌照护的临床优先事项。
研究设计与样本
- 专家视角文章,讨论PSMA PET在前列腺癌管理中的演变角色、可及性不均的临床后果及欧洲实施优先事项。
主要发现
- PSMA PET在高风险疾病初诊分期和生化复发中改善疾病特征描述,诊断性能优于传统影像。
- PSMA PET日益影响治疗规划、患者分层和多学科决策。
- 报销政策、监管框架、示踪剂供应、影像容量、转诊路径和本地专业能力差异可能限制合格患者及时获得PSMA PET。
- 可及性差异可能影响分期准确性、复发疾病定位、治疗选择和照护公平性。
临床怎么用
- 在高风险前列腺癌初诊分期和生化复发评估中应考虑PSMA PET以改善疾病特征描述。
- 利用PSMA PET结果支持治疗规划、患者分层和多学科决策。
- 关注本地报销、示踪剂供应和转诊路径等可及性因素对合格患者及时检查的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prostate-specific membrane antigen positron emission tomography (PSMA PET) has become an integral component of contemporary prostate cancer (PCa) management, improving disease characterization in clinically relevant settings such as initial staging of higher-risk disease and biochemical recurrence. Beyond its superior diagnostic performance compared with conventional imaging, PSMA PET increasingly influences treatment planning, patient stratification, and multidisciplinary decision-making. However, despite growing incorporation into international clinical guidelines, access to PSMA PET remains heterogeneous across health care systems. Variability in reimbursement policies, regulatory frameworks, tracer availability, imaging capacity, referral pathways, and local expertise may limit timely access for eligible patients. These disparities have important clinical implications, potentially affecting staging accuracy, localization of recurrent disease, treatment selection, and equity of care. In this expert perspective, we discuss the evolving role of PSMA PET in PCa management, highlight the clinical consequences of unequal access, and identify key priorities to facilitate implementation across Europe. Improving access to high-quality PSMA PET should be regarded not only as a logistical objective but also as a clinical priority to ensure that advances in molecular imaging translate into more precise, timely, and equitable PCa care.
引用
- Peyrottes A, Turpin L, Hernández LF, et al. PSMA PET in Prostate Cancer: Clinical Value, Access Challenges, and Priorities for Implementation. Eur Urol Oncol. 2026. PMID: 42552166. doi:10.1016/j.euo.2026.07.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。